In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A ‘Blood Pressure Test’ For Dementia

Neuroscience Innovator Looks At Early Diagnosis From New Angle

Executive Summary

The attention accorded to dementia, MCI and degenerative brain conditions has been slow to reach the levels given to the more visibly-quantifiable conditions, such as cardiovascular disease and oncology. But earlier detection of cognitive impairment is a priority, despite therapies not yet being available to halt or reverse the conditions. Playing its part to push back the boundaries is Cognetivity Neurosciences, a London-based company with an innovative tool that uses AI to test subjects for the early signs of dementia.

You may also be interested in...



Finding A Rock ‘n Roll Moment In Dementia Diagnostics

Find a problem and develop the solution for it: so goes the accepted wisdom for successful health care technology adoption. But as Cognetivity Neurosciences CEO Sina Habibi demonstrates, the reverse can also provide a very valid business pathway.

MTI Outlook 2020: Global Health Systems Are Learning To Embrace AI As A Force For Good

The term artificial intelligence was coined at the Dartmouth Summer Research Project in 1956, but it is only in very recent years that it has been consistently at the top of the agenda in discussions on the future direction of health care. AI is now increasingly seen as a realistic solution to demand overload on clinicians. At the same time, techno-fears are abating. This confluence will transform health care radically in the next two decades.  

Global Health Systems Are Learning To Embrace AI As A Force For Good

The term artificial intelligence was coined at the Dartmouth Summer Research Project in 1956, but it is only in very recent years that it has been consistently at the top of the agenda in discussions on the future direction of health care. As a tool to improve both the quality and speed of care, AI is now increasingly seen as a realistic solution to the demand overload on clinicians. At the same time, techno-fears are abating. This confluence will transform health care radically in the next two decades.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

IV124286

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel